Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 145,369 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorders Clear all

Conditions: Benign Prostatic Hyperplasia, Enlarged Prostate
Interventions: Tadalafil, Placebo, Finasteride; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 45 Years and older · Male only
Enrollment: 696 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 10
States / cities: Davis, California • Fresno, California • Laguna Hills, California + 7 more

Conditions: Stable Angina
Interventions: T89(Dantonic); Drug
Lead sponsor: Tasly Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Multiple Myeloma
Interventions: Melphalan, Panobinostat; Drug
Lead sponsor: Oncotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 4
States / cities: Bakersfield, California • West Hollywood, California • Denver, Colorado + 1 more

Conditions: Alcoholism
Interventions: Motivational Enhancement Therapy, Cognitive Behavioral Therapy, FC Assessment, IB Assessment; Behavioral · Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Essential Tremor
Interventions: Encora X1; Device
Lead sponsor: Encora, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer
Interventions: epirubicin, vinorelbine; Drug
Lead sponsor: University of Medicine and Dentistry of New Jersey; Other
Eligibility: 21 Years to 120 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Severe Hypertriglyceridemia
Interventions: placebo, omefas; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 30
States / cities: National City, California • Sacramento, California • Manchester, Connecticut + 25 more

Conditions: Obstructive Sleep Apnea
Interventions: MRI, DISE, and Surgery; Procedure
Lead sponsor: University of Southern California; Other
Eligibility: 21 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Melanoma (Skin)
Interventions: O6-benzylguanine, carmustine; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 13
States / cities: Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 8 more

Conditions: Pancreatic Cancer
Interventions: gemcitabine hydrochloride, tacedinaline; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2001
U.S. locations: 11
States / cities: Los Angeles, California • Tampa, Florida • Baltimore, Maryland + 8 more

Conditions: Cerebral Palsy, Spastic
Interventions: Dynamic Wheelchair Seating System; Device
Lead sponsor: Montana State University; Other
Eligibility: 4 Years to 12 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Bozeman, Montana

Conditions: Lymphoma
Interventions: RevM10 gene, RevM10/polAS gene, in vitro-treated peripheral blood stem cell transplantation, peripheral blood stem cell transplantation; Biological · Procedure
Lead sponsor: Systemix; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 6
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 2 more

Conditions: Absence Seizures, Absence Epilepsy
Interventions: Epihunter; Device
Lead sponsor: Epihunter NV; Industry
Eligibility: 4 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Trisomy 13 Syndrome, Arthrogryposis Congenita Multiplex With Intestinal Atresia, Asparagine Synthetase Deficiency, CHARGE Syndrome, Early Infantile Epileptic Encephalopathy, FOXG1 Syndrome, KBG Syndrome, Noonan Syndrome, Severe Hemophilia A, Short Bowel Syndrome, Beta-Propeller Protein-Associated Neurodegeneration, Brain Injury of Prematurity With Periventricular Leukomalacia, Chromosome 17p13.3 Microdeletion Syndrome, Chromosome 1q43-1q44 Deletion, Cockayne Syndrome, Congenital Diaphragmatic Hernia, End-Stage Renal Disease With Cloacal Anomaly, Mitochondrial Depletion Disorder, Severe Factor VII Deficiency
Interventions: Family Centered pediatric palliative care for family caregivers of children with rare diseases.; Behavioral
Lead sponsor: Children's National Research Institute; Other
Eligibility: 12 Months to 99 Years
Enrollment: 480 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Obesity
Interventions: Phentermine-Topiramate Extended Release, Placebo, Online support system; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Allergic Conjunctivitis
Interventions: Ketotifen/naphazoline, Ketotifen, Naphazoline, Vehicle; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 6 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: North Andover, Massachusetts

Conditions: Primary or Metastatic Lung Tumors
Interventions: AuroLase Therapy; Device
Lead sponsor: Nanospectra Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancer, Advanced Unresectable Gastric Cancer
Interventions: BAY 43-9006, docetaxel, cisplatin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Obstructive Pulmonary Disease (COPD), Emphysema
Interventions: Home Based Pulmonary Rehabilitation; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 40 Years to 99 Years
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Jacksonville, Florida • Minneapolis, Minnesota • Rochester, Minnesota

Conditions: Prostate Cancer
Interventions: Hypofractionated therapy; Radiation
Lead sponsor: Timothy Showalter, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 3
States / cities: Charlottesville, Virginia • Norton, Virginia • Richmond, Virginia

Conditions: Fanconi Anemia
Interventions: Eltrombopag; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 6 Years to 99 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Substance Abuse Disorder
Interventions: Low intensity care, Voucher reinforcement; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Insomnia Disorder
Interventions: Tasimelteon Oral Suspension, Placebo; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 21
States / cities: Dothan, Alabama • Phoenix, Arizona • Irvine, California + 17 more

Conditions: Major Depressive Disorder
Interventions: MECTA Spectrum 5000Q Amplitude; Device
Lead sponsor: University of New Mexico; Other
Eligibility: 50 Years to 80 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Search by objective public record fields.

A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms

A Study To Evaluate The Effect of T89(Dantonic®)On P450 Enzymes

Melphalan and Panobinostat (LBH589) for the Treatment of Patients With Recurrent Multiple Myeloma

Evaluating Interventions for Alcohol Use Disorder

The Encora X1™ in a Real World Observational Study

Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer

Epanova® for Lowering Very High Triglycerides

Magnetic Resonance Imaging in Obstructive Sleep Apnea

O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma

Gemcitabine With or Without CI-994 in Treating Patients With Advanced Pancreatic Cancer

Effects of Dynamic Wheelchair Seating on Spasticity and Functional Mobility in Children

Gene Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma

ECV - Epihunter Clinical Validation

Palliative Care Needs of Children With Rare Diseases and Their Families

Anti-Obesity Phentermine-Topiramate Extended Release Pharmacotherapy vs Placebo Among Patients Using a Wearable Activity Tracker

Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.

Efficacy Study of AuroLase Therapy in Subjects With Primary and/or Metastatic Lung Tumors

Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer

Home Pulmonary Rehabilitation for COPD

Shorter Duration Radiotherapy to Treat Prostate Cancer After Removal of the Prostate

Eltrombopag for Fanconi Anemia

Evaluating Three Methods for Helping Syringe Exchangers Begin Methadone Maintenance

Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia

ECT Pulse Amplitude and Medial Temporal Lobe Engagement